Comparative Pharmacology
Head-to-head clinical analysis: MAXOLON versus PROMETHAZINE DM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAXOLON versus PROMETHAZINE DM.
MAXOLON vs PROMETHAZINE DM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metoclopramide, the active ingredient in MAXOLON, is a dopamine D2 receptor antagonist and also enhances the response to acetylcholine at muscarinic receptors in the gastrointestinal tract, leading to increased gastric motility and accelerated gastric emptying. It also has antiemetic effects by blocking dopamine receptors in the chemoreceptor trigger zone (CTZ).
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist, antiemetic via blockade of dopamine D2 receptors in the chemoreceptor trigger zone, and sedative via central anticholinergic effects. Dextromethorphan is an NMDA receptor antagonist and sigma-1 receptor agonist, suppressing cough by central action on the cough center.
10 mg orally, intramuscularly, or intravenously three to four times daily. Maximum daily dose: 30 mg or 0.5 mg/kg.
2 teaspoonfuls (10 mL) orally every 4-6 hours, not to exceed 8 teaspoonfuls (40 mL) per 24 hours.
None Documented
None Documented
5-6 hours in adults with normal renal function; prolonged to 15-20 hours in severe renal impairment (CrCl <10 mL/min).
16-19 hours (terminal); note: effect may last longer due to active metabolites and tissue binding
Renal: 85-95% as unchanged drug and metabolites; biliary/fecal: <5%.
Renal (70-80% as metabolites, <1% unchanged); biliary/fecal (20-30%)
Category C
Category A/B
Antiemetic
Antihistamine / Antiemetic